单药或联合免疫检查点抑制剂治疗的癌症患者免疫检查点抑制剂相关结肠炎的影像与临床表现
回顾性分析1044例接受免疫检查点抑制剂(ICI)治疗的癌症患者,48例临床诊断免疫相关结肠炎,其中34例有影像学证据。中位起病时间单药组75天、联合组78天;最常见影像表现为肠壁增厚(97%)和结肠积液(82.3%),影像表现两组间无显著差异;联合组其他免疫相关不良事件(irAEs)发生率27.8%(5/18)显著高于单药组0%(p=0.046)。
要点
- ICI相关结肠炎影像最常见为肠壁增厚(97%)和结肠积液(82.3%),61.8%呈弥漫性结肠炎。
- 单药与联合治疗的影像表现无显著差异(p>0.05)。
- 联合治疗患者更常合并其他irAEs(5/18,27.8% vs 单药组0%,p=0.046)。
关键影像表现/征象
- 肠壁增厚见于33/34(97%)患者。
- 结肠积液见于28/34(82.3%)患者。
- 弥漫性结肠炎见于21/34(61.8%)患者。
诊断标准与关键数值
- 单药组(第1组)自ICI开始至结肠炎中位起病时间为75天(IQR 25-75,49.5-216天)。
- 联合治疗组(第2组)自ICI开始至结肠炎中位起病时间为78天(IQR 25-75,44.3-99.5天)。
- 症状包括腹泻91.1%(31/34)、恶心/呕吐52.9%(18/34)、腹痛52.9%(18/34)。
- 两组影像表现比较p>0.05。
- 第2组其他irAEs为5/18(27.8%),第1组为0,p=0.046。
临床应用与阅片要点
- 接受ICI治疗的患者出现腹泻、恶心/呕吐或腹痛时,应关注影像上肠壁增厚和结肠积液等结肠炎征象。
- 单药与联合治疗的影像表现无显著差异,阅片时不能依据治疗类型区分。
- 联合治疗患者出现结肠炎时,需注意可能合并其他irAEs。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To determine the frequency, imaging, and clinical manifestations of immune checkpoint inhibitor (ICI)-related colitis in cancer patients on monotherapy or combination therapy.
METHODS: The electronic medical records of 1044 cancer patients who received ICIs were retrospectively reviewed to identify 48 patients who had a clinical diagnosis of immune-related colitis. Imaging studies were reviewed to identify patients with imaging manifestations of colitis. Demographic data, type of ICIs, symptoms, presence of other immune-related adverse events (irAEs), and management were recorded.
RESULTS: There was imaging evidence of immune-related colitis in 34 patients (24 men; median age: 63.5 years). The median time to onset of colitis was 75 days (IQR 25-75, 49.5-216 days) in patients receiving monotherapy (group 1) and 78 days (IQR 25-75, 44.3-99.5 days) in patients undergoing combination therapy (group 2) following start of ICI. Symptoms included diarrhea (91.1% [31 of 34]), nausea/vomiting (52.9% [18 of 34]), and abdominal pain (52.9% [18 of 34]). The most common imaging findings were bowel wall thickening (97% [33 of 34]) and fluid-filled colon (82.3% [28 of 34]). Colitis was diffuse in 21 of 34 (61.8%) patients. Imaging manifestations did not differ between the two groups (p > 0.05). Steroids and antibiotics were used to treat colitis in 29 of 34 (85.2%) and 13 of 34 (38.2%) patients, respectively. No patients in group 1 experienced concurrent irAEs, but 5 of 18 (27.8%) of patients in group 2 had other irAEs (p = 0.046).
CONCLUSION: Immune-related colitis occurred in 3.3% of patients receiving ICIs with bowel wall thickening, fluid-filled colon and pancolitis being the most common imaging manifestations. Imaging manifestations did not differ between patients receiving monotherapy or combination therapy. However, concurrent irAEs were significantly observed in patients undergoing combination therapy.
引用
- Shieh AC, Guler E, Pfau D, et al. Imaging and clinical manifestations of immune checkpoint inhibitor-related colitis in cancer patients treated with monotherapy or combination therapy. Abdom Radiol (NY). 2020. PMID: 31754740. doi:10.1007/s00261-019-02334-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。